Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis

Leukemia Research

Volumn 28, Issue 8, 2004, Pages 845-850

  Kelley, Todd W ^a   Alkan, Serhan ^b   Srkalovic, Gordan ^c   Hsi, Eric D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Bortezomib; Chronic lymphocytic leukemia; NF kappa B; Proteasome inhibitor

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME INHIBITOR;

ANALYTIC METHOD; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; INCUBATION TIME; LEUKEMIA; LEUKEMIA CELL; PRIORITY JOURNAL; TIMED DRUG RELEASE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CYSTEINE ENDOPEPTIDASES; FLOW CYTOMETRY; HUMANS; LEUKEMIA, B-CELL, CHRONIC; LYMPHOCYTES; MULTIENZYME COMPLEXES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TUMOR CELLS, CULTURED;

EID: 2942594286     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.12.010     Document Type: Article

References (13)

1. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 94:1999;1840-1847
2. H genes are associated with a more aggressive form of chronic lymnphocytic leukemia. Blood. 94:1999;1848-1854
3. Garg A., Aggarwal B.B. Nuclear transcription factor-kappa B as a target for cancer drug development. Leukemia. 16:2002;1053-1068
4. Furman R., Asgary Z., Mascarenhas J.O., Liou H.C., Schattner E.J. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia cells. J. Immunol. 164:2000;2200-2206
5. L. Mol. Cell. Biol. 20:2000;2687-2695
6. Guttridge D.C., Albanese C., Reuther J.Y., Pestell R.G., Baldwin A.S. NF-kappa B controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19:1999;5785-5799
7. LeBlanc R., Catley L.P., Hideshima T., Lentzsch S., Mitsiades C.S., Mitsiades N., et al. Proteasome inhibitor PS-341 inhibits myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62:2002;4996-5000
8. Mitsiades N., Mitsiades C.S., Richardson P.G., Poulaki V., Tai Y.T., Chauhan D., et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 101:2003;2377-2380
9. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A phase II study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348:2003;2609-2617
10. Aghajanian C., Soignet S., Dizon D.S., Pien C.S., Adams J., Elliott P.J., et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 8:2002;2505-2511
11. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., Shea T.C., Baldwin A.S., Stahl S., et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20:2002;4420-4427
12. Almond J.B., Snowden R.T., Hunter A., Dinsdale D., Cain K., Cohen G.M. Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf1-containing apoptosome complex. Leukemia. 15:2001;1388-1397
13. Crespo M., Bosch F., Villamor N., Bellosillo B., Colomer D., Rozman M., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. 348:2003;1764-1775